Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence
Wesam Bazzar, Matteo Bocci, Eduar Hejll, Vedrana Tabor, Per Hydbring, Alf Grandien, Mohammad Alzrigat, Lars‐Gunnar Larsson
Abstract
-driven AML linked to senescence induction. Our results suggest that CDK2 is a promising target for pro-senescence cancer therapy, in particular for MYC-driven tumors, including leukemia.
Topics & Concepts
BiologySenescenceCancer researchCarcinogenesisCyclin-dependent kinase 2ApoptosisCell cycleHaematopoiesisCyclinOncogeneBcl-xLKinaseLeukemiaStem cellImmunologyProgrammed cell deathCell biologyCancerBiochemistryGeneticsCancer-related Molecular PathwaysAcute Myeloid Leukemia ResearchProtein Degradation and Inhibitors